The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 3, 2015, Pages 481-487

  Ribeiro Oliveira, Antônio ^a   Marques, Mirna B ^a,b   Vilas Boas, Walkiria W ^a   Guimarães, Jonas ^a   Coimbra, Cândido C ^a   Anjos, Allan P ^a   Fóscolo, Rodrigo B ^a   Santos, Robson ^a   Thomas, Julia D ^b   Igreja, Suzana M ^b   Kola, Blerina ^b   Grossman, Ashley B ^b,c   Korbonits, Márta ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

AMP activated protein kinase; angiotensin receptor blocker; candesartan; stress; surgery

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; CANDESARTAN; PROTEIN KINASE; UNCLASSIFIED DRUG; ADENYLATE KINASE; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; ENZYME ACTIVITY; ENZYME ASSAY; GENERAL ANESTHESIA; HEART; LAPAROTOMY; LIVER LEVEL; LONG TERM CARE; NONHUMAN; RAT; SURGICAL STRESS; ANIMAL; CARDIAC MUSCLE; DRUG EFFECTS; ENZYMOLOGY; LIVER; MALE; METABOLISM; PHYSIOLOGICAL STRESS; WISTAR RAT;

ADENYLATE KINASE; ANIMALS; BENZIMIDAZOLES; LAPAROTOMY; LIVER; MALE; MYOCARDIUM; RATS, WISTAR; STRESS, PHYSIOLOGICAL; TETRAZOLES;

EID: 84950322704     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313499199     Document Type: Article

References (42)

1. Hardie DG, Hawley SA, Scott JW., AMP-activated protein kinase-development of the energy sensor concept. J Physiol (Lond) 2006; 574: 7-15.
2. Hardie DG, Ross FA, Hawley SA., AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251-262.
3. Kahn BB, Alquier T, Carling D, et al. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25.
4. Pacak K., Stressor-specific activation of the hypothalamic-pituitary-adrenocortical axis. Physiol Res 2000; 49: S11-S17.
5. Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: A novel mechanism in Cushing's syndrome. FASEB J 2008; 22: 1672-1683.
6. Nagata D, Hirata Y., The role of AMP-activated protein kinase in the cardiovascular system. Hypertens Res 2010; 33: 22-28.
7. Yoshida D, Higashiura K, Shinshi Y, et al. Effects of angiotensin II receptor blockade on glucose metabolism via AMP-activated protein kinase in insulin-resistant hypertensive rats. J Am Soc Hypertens 2009; 3: 3-8.
8. Atmaca A, Gedik O., Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes. Adv Ther 2006; 23: 615-622.
9. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, et al. The renin-angiotensin system and diabetes: An update. Vasc Health Risk Manag 2008; 4: 787-803.
10. Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg 2005; 100: 636-644.
11. McBride A, Hardie DG., AMP-activated protein kinase-a sensor of glycogen as well as AMP and ATP? Acta Physiol (Oxf) 2009; 196: 99-113.
12. Marques MB, Ribeiro-Oliveira A Jr, Guimaraes J, et al. Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker. Stress 2012; 15: 554-561.
13. Jones ES, Black MJ, Widdop RE., Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 2004; 37: 1023-1030.
14. De Cavanagh EM, Toblli JE, Ferder L, et al. Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats. Cell Mol Biol 2005; 51: 573-578.
15. Reis FM, Ribeiro-de-Oliveira A Jr, Guerra RM, et al. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress. Life Sci 1996; 58: 155-161.
16. Ribeiro-de-Oliveira A Jr, Guerra RM, Foscolo RB, et al. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats. J Endocrinol 1999; 162: 237-242.
17. Ribeiro-de-Oliveira A, Guerra RM, Foscolo RB, et al. Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint. Pharmacol Biochem Behav 2001; 68: 229-233.
18. Yamada F, Inoue S, Saitoh T, et al. Glucoregulatory hormones in the immobilization stress-induced increase of plasma glucose in fasted and fed rats. Endocrinology 1993; 132: 2199-2205.
19. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.1-28.16.
20. Saavedra JM, Benicky J., Brain and peripheral angiotensin II play a major role in stress. Stress 2007; 10: 185-193.
21. Nagata D, Takeda R, Sata M, et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004; 110: 444-451.
22. Ramamurthy S, Ronnett GV., Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol (Lond) 2006; 574: 85-93.
23. Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J Cell Mol Med 2011; 15: 1572-1581.
24. Viollet B, Guigas B, Leclerc J, et al. AMP-activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009; 196: 81-98.
25. Zorad S, Dou JT, Benicky J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006; 552: 112-122.
26. Yamauchi T, Kadowaki T., Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 2008; 32: S13-S18.
27. Yang SJ, Choi JM, Chae SW, et al. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS One 2011; 6: e17057.
28. Fang F, Liu GC, Kim C, et al. Adiponectin attenuates angiotensin II-induced oxidative stress in renal tubular cells through AMPK and cAMP-Epac signal transduction pathways. Am J Physiol Renal Physiol 2013; 304: F1366-F1374.
29. Erbe DV, Gartrell K, Zhang YL, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45: 154-162.
30. Fukuda M, Nakamura T, Kataoka K, et al. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J Hypertens 2010; 28: 340-352.
31. Georgescu EF., Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? Adv Ther 2008; 25: 1141-1174.
32. Munger MA., Use of Angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. P T 2011; 36: 22-40.
33. Murca TM, Moraes PL, Capuruco CA, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept 2012; 177: 107-115.
34. Changmin H, Jianguo C, Dongming L, et al. Effects of xylazole alone and in combination with ketamine on the metabolic and neurohumoral responses in healthy dogs. Vet Anaesth Analg 2010; 4: 322-328.
35. Li M, Zhao J, Hu Y, et al. Oxygen free radicals regulate energy metabolism via AMPK pathway following cerebral ischemia. Neurol Res 2009; 32: 779-784.
36. Kola B., Role of AMP-activated protein kinase in the control of appetite. J Neuroendocrinol 2008; 20: 942-951.
37. Machado LJ, Marubayashi U, Reis AM, et al. The hyperglycemia induced by angiotensin II in rats is mediated by AT1 receptors. Braz J Med Biol Res 1998; 31: 1349-1352.
38. Bregonzio C, Seltzer A, Armando I, et al. Angiotensin II AT(1) receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress 2008; 11: 457-466.
39. Saavedra JM, Ando H, Armando I, et al. Brain angiotensin II, an important stress hormone: Regulatory sites and therapeutic opportunities. Ann N Y Acad Sci 2004; 1018: 76-84.
40. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
41. Choi SL, Kim SJ, Lee KT, et al. The regulation of AMP-activated protein kinase by H(2)O(2). Biochem Biophys Res Commun 2001; 287: 92-97.
42. Pang CC., Vasopressin and angiotensin in the control of arterial pressure and regional blood flow in anaesthetized, surgically stressed rats. Can J Physiol Pharmacol 1983; 61: 1494-1500.